leisure time -WSS

leisure time

author：knowledge 2025-09-29 16:35:08 - browse：71364

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Medicare to pay more for cardiac rehab in hospital outpatient clinics

focus

WSS

Listen: PBM conflicts, RSV vaccines, & the future of flu season

FDA panel to weigh safety of artificial wombs for preterm births

Doctor appointment wait times are getting worse

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Free Covid tests will again be offered to all U.S. households

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

hotspot

leisure time

focus

Heart attack and stroke risk calculators need revising

People with substance use disorder deserve online privacy

The cancer drug shortage isn’t new — and neither are the solutions

People with substance use disorder deserve online privacy

Moonlake's readout produced a cash windfall. Risks remain

Akili changes sales model for its ADHD video game treatment

Cancer drug shortages should be causing more outrage

RaDonda Vaught case: a double standard for nurses, physicians

23andMe had bad news about my health. I wish a person had delivered it

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

hotspot

Covid’s new normal has set in amid another rise in cases

Fed up with FDA, ALS advocates consider a take

Covid’s new normal has set in amid another rise in cases

Pfizer's Covid pill remains 89% effective in final analysis, company says

Fed up with FDA, ALS advocates consider a take

Fed up with FDA, ALS advocates consider a take

Wikipedia

knowledge

focus

leisure time